文献速递核素与放射性配体治疗肿瘤 PET/CT

177Lu-FAPI-2286放射性配体治疗难治性头皮黑色素瘤

177 Lu-FAPI-2286 Radioligand Therapy in Refractory Scalp Melanoma.
PubMed 文献 · Clin Nucl Med · 2026-09-10

一例66岁男性不可手术头皮恶性黑色素瘤患者,免疫治疗难治,99mTc-HYNIC-TOC SPECT/CT未见 scalp 病灶摄取,排除177Lu-DOTATATE治疗;疾病进展后99mTc-FAPI-46 SPECT/CT显示病灶强烈摄取,遂行177Lu-FAPI-2286放射性配体治疗,4周期后所有病灶退缩并转诊手术。本病例说明FAPI诊疗一体化在黑色素瘤中的临床价值,99mTc-FAPI SPECT/CT可直接指导177Lu-FAPI靶向放射性配体治疗。

要点

  • 99mTc-HYNIC-TOC SPECT/CT无摄取可排除177Lu-DOTATATE治疗。
  • 99mTc-FAPI-46 SPECT/CT强烈摄取可指导177Lu-FAPI-2286治疗。
  • 4周期177Lu-FAPI-2286后所有病灶退缩并转诊手术。

核心结论

  • FAPI诊疗一体化可扩展黑色素瘤的治疗选择。
  • 99mTc-FAPI SPECT/CT可直接指导177Lu-FAPI靶向放射性配体治疗。

研究设计与样本

  • 单例病例报告:66岁男性不可手术头皮恶性黑色素瘤,免疫治疗难治。

主要发现

  • 99mTc-HYNIC-TOC SPECT/CT示头皮病灶无 tracer 摄取,排除177Lu-DOTATATE治疗。
  • 疾病进展后99mTc-FAPI-46 SPECT/CT示病灶强烈 tracer 摄取。
  • 177Lu-FAPI-2286治疗4周期后所有病灶退缩,患者转诊肿瘤切除。

临床怎么用

  • 对免疫治疗难治的黑色素瘤,可用99mTc-FAPI SPECT/CT评估FAPI靶向治疗可行性。
  • 99mTc-HYNIC-TOC SPECT/CT无摄取时不宜行177Lu-DOTATATE治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 66-year-old man with inoperable malignant scalp melanoma, refractory to immunotherapy, underwent 99m Tc-HYNIC-TOC SPECT/CT for evaluating the possibility of radioligand therapy with 177 Lu-DOTATATE, which demonstrated no tracer uptake in scalp lesions, precluding 177 Lu-DOTATATE therapy. Subsequent disease progression prompted 99m Tc-FAPI-46 SPECT/CT, which showed intense tracer uptake in lesions and prompted radioligand therapy with 177 Lu-FAPI-2286. After 4 cycles of treatment, all lesions showed regression and he was referred for tumor resection. This case illustrates the clinical utility of FAPI-based theranostic and shows 99m Tc-FAPI SPECT/CT can directly inform targeted radioligand therapy using 177 Lu-FAPI, thereby expanding therapeutic options in melanoma management.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Elahifard H, Samadi MH, Bari A, et al. 177 Lu-FAPI-2286 Radioligand Therapy in Refractory Scalp Melanoma. Clin Nucl Med. 2026. PMID: 42725461. doi:10.1097/RLU.0000000000006681

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。